Two vaccines sit ready, waiting for permission to be used.
Two H5N1 vaccines stand ready, tested and waiting, while a bureaucratic and political clock ticks down. A severe case in Louisiana — the first of its kind — has sharpened the debate over whether the Biden administration will authorize their use before a new administration, led by figures skeptical of vaccines, takes power on January 20th. At stake is not merely a regulatory decision, but the question of whether a society can act on what it knows before the moment to act has passed.
- A Louisiana resident's severe H5N1 hospitalization — the first serious U.S. case — has cracked open the assumption that this outbreak would remain mild and contained to farmworkers.
- Public health veterans, including former FDA chief Scott Gottlieb and ex-COVID coordinator Deborah Birx, are sounding alarms that limited testing means 66 confirmed cases is almost certainly a dangerous undercount.
- The clock is the crisis: health experts are urging the Biden administration to authorize two ready-made vaccines before January 20th, when an incoming HHS secretary with a long record of vaccine skepticism assumes control.
- The Biden administration has so far declined to authorize the vaccines, though officials have left the door open if conditions worsen — a threshold some argue the Louisiana case has already crossed.
- Nearly 900 dairy herds across 16 states are now affected, yet no person-to-person transmission has been confirmed, leaving the CDC to hold its position that general public risk remains low — a stance critics call dangerously complacent.
Two H5N1 vaccines exist, have been tested, and are ready for use. What they lack is authorization — and the window to secure it may be closing fast.
The urgency sharpened in early December when a Louisiana resident was hospitalized with severe H5N1 illness after exposure to a backyard flock of sick and dead birds. It was the first serious case the country had recorded. Until then, the 66 confirmed human cases across ten states had been mostly mild infections among farmworkers and poultry handlers. This case changed the calculus.
Dr. Leana Wen, former Baltimore health commissioner, made the case publicly on CBS: the Biden administration could authorize the vaccines now and begin distributing them to farmworkers and other high-risk groups immediately. The concern is what happens if it doesn't. Donald Trump takes office January 20th, and his pick for HHS secretary, Robert F. Kennedy Jr., has spent years promoting vaccine claims that science has thoroughly debunked — raising fears that authorization could be delayed or blocked under new leadership.
The Biden administration had said as recently as this month that no authorization was planned, though officials acknowledged the position could shift if the outbreak worsened. Some argued that threshold had already been met. Meanwhile, experts including Dr. Deborah Birx warned that limited testing meant the official case count was almost certainly an undercount, with asymptomatic spread going undetected. Scott Gottlieb wrote bluntly that if H5N1 became a pandemic, the country would have only itself to blame.
The CDC defended its record, pointing to expanded testing guidance issued in November and year-round hospital surveillance. It noted that no person-to-person transmission had been documented and that the general public remained at low risk — even as the virus had quietly spread to nearly 900 dairy herds across 16 states since March.
The vaccines are ready. The question now is whether the decision to use them will be made by those who have the will, before the moment passes to those who may not.
Two vaccines for H5N1 bird flu sit ready on the shelf, waiting for permission to be used. They exist. They work. But they cannot be administered to a single person until the Food and Drug Administration signs off—and that authorization has not come, despite mounting pressure from public health experts who see a narrowing window of opportunity.
The urgency stems from a collision of timelines. In early December, a person in Louisiana was hospitalized with severe illness from H5N1, marking the first serious case the country has recorded. It was not a mild infection. The patient had been exposed to a backyard flock of sick and dead birds. Until that moment, nearly all of the 66 confirmed human cases across ten states had been farmworkers or poultry handlers with direct contact to infected animals, and their illnesses had been relatively light. This case changed the calculus.
Dr. Leana Wen, former health commissioner of Baltimore, went on CBS's Face the Nation to make a direct argument: the Biden administration could authorize the vaccine today and begin distributing it immediately to farmworkers and other vulnerable populations. The window to act, she suggested, was closing. In less than three weeks, Donald Trump would take office, and his choice for secretary of health and human services—Robert F. Kennedy Jr.—is a well-known skeptic of vaccines. Though Kennedy has insisted he is not anti-vaccine, he has spent years promoting claims about vaccines that scientific evidence has thoroughly debunked. The risk, Wen and others argued, was that a new administration might slow or block authorization entirely.
The Biden administration had said as recently as this month that there were no plans to authorize a vaccine, though officials acknowledged that stance could shift if the outbreak worsened. Dr. Nirav Shah, the principal deputy director of the CDC, had suggested the agency would consider moving forward with authorization if the virus began causing serious illness in people. That threshold, some argued, had now been crossed.
But the full picture of how many people have actually been infected remains unclear. Testing for H5N1 has been limited, and Wen stated flatly that the official count of 66 cases was "almost certainly" an undercount. Dr. Deborah Birx, who coordinated the White House's COVID-19 response during Trump's first term, echoed the concern on CNN, saying the country was "not testing enough" and that asymptomatic spread—which can be substantial with respiratory viruses—was being overlooked. Scott Gottlieb, who led the FDA under Trump, wrote on social media that if H5N1 became a pandemic, the nation "will have only itself to blame," pointing to failures by agricultural officials who had hoped the virus would burn itself out rather than taking aggressive preventive steps.
The CDC pushed back against some of this criticism, noting that it had widened its testing recommendations in November to include asymptomatic people with high-risk exposure and had instructed hospitals to continue monitoring flu viruses year-round rather than scaling back surveillance at season's end. Still, the agency acknowledged that the virus had spread to nearly 900 dairy herds across 16 states since first being detected in U.S. cattle in March. The general public remained at low risk, the CDC maintained, with no documented cases of person-to-person transmission.
The practical question now is whether the Biden administration will move before January 20th. If it does not, the decision will fall to an incoming team led by someone whose skepticism of vaccines is well documented. The two vaccines are ready. The question is whether they will ever be authorized to protect the people who need them most.
Citas Notables
They could get the vaccine authorized now and get it out to farmworkers and vulnerable people. I think that's the right approach, because we don't know what the Trump administration is going to be doing around bird flu.— Dr. Leana Wen, former Baltimore health commissioner
If H5N1 develops into a pandemic, the U.S. will have only itself to blame. Agricultural officials did just about everything wrong over last year, hoping the virus would burn out and it didn't.— Scott Gottlieb, former FDA commissioner
La Conversación del Hearth Otra perspectiva de la historia
Why hasn't the FDA just approved these vaccines already if they're ready?
Because the FDA requires authorization before any vaccine can be used, and the Biden administration has said there's no plan to seek that authorization yet. They're waiting to see if the outbreak gets worse.
But a person was just hospitalized with severe illness. Isn't that worse?
That's exactly what the experts are arguing. Wen and others say that case crossed the threshold for action. But the administration seems to be treating it as an isolated incident rather than a signal to move.
What changes when Trump takes office?
His pick for health secretary is Robert Kennedy Jr., who has spent years promoting vaccine skepticism. The fear is that an administration led by someone with those views might be slower to authorize a vaccine, or might not authorize it at all.
Are we talking about a real pandemic risk here?
The CDC says the risk to the general public is still low. But the virus has infected nearly 900 dairy herds in 16 states since March. It's spreading. And we might not even know how many people have been infected because testing has been limited.
So the real problem is we don't know what we're dealing with?
Partly. We know it's in animals and it's jumping to people. We know one person got seriously sick. But we're not testing widely enough to see the full picture. That's what makes the decision to authorize a vaccine now seem urgent to some people—you act before you're certain, not after.
And if they don't authorize it before Trump takes office?
Then it becomes a question of whether the new administration will prioritize it. Given Kennedy's track record, that's uncertain.